tetano
Editor, Senior Moderator
EBioMedicine
. 2026 Jul 16:130:106387.
doi: 10.1016/j.ebiom.2026.106387. Online ahead of print.
Autoantibodies against type I interferons in patients with zoonotic H7N9 influenza: an observational case-control study
Yongkun Chen[SUP] 1 [/SUP], Jakob Ankerhold[SUP] 2 [/SUP], Tingting Jia[SUP] 3 [/SUP], Martin Wolkewitz[SUP] 4 [/SUP], Jonas Fuchs[SUP] 5 [/SUP], Lifang Yuan[SUP] 1 [/SUP], Tian Bai[SUP] 6 [/SUP], Kevin Groen[SUP] 7 [/SUP], Roger Kuratli[SUP] 7 [/SUP], Benjamin G Hale[SUP] 7 [/SUP], Georg Kochs[SUP] 5 [/SUP], Dayan Wang[SUP] 8 [/SUP], Martin Schwemmle[SUP] 5 [/SUP], Yuelong Shu[SUP] 9 [/SUP], Laura Graf[SUP] 10 [/SUP]
Affiliations
Background: The determinants of the species barrier preventing human infections with avian influenza A viruses (IAV) are incompletely understood. We previously identified loss-of-function variants of the interferon-regulated antiviral factor MxA as a genetic factor for increased susceptibility to infections with the H7N9 subtype. Given the central role of type I IFNs (IFN-I) in antiviral defence, we hypothesised that IFN-I-neutralising autoantibodies may similarly predispose to zoonotic H7N9 infection.
Methods: In this observational case-control study, serum samples collected between 2013 and 2017 from 199 Chinese patients with laboratory-confirmed H7N9 infection and 531 healthy, uninfected controls (269 poultry workers, 262 close contacts) were screened for IgG autoantibodies binding IFNα[SUB]2[/SUB], IFNβ[SUB]1b[/SUB], or IFNω using a multiplex bead-based assay. Positive samples were tested for IFN-neutralising activity in a luciferase-based reporter assay. To confirm their ability to block IFNα[SUB]2[/SUB]-mediated antiviral activity, selected samples (n = 19) were analysed in IAV infection experiments. Associations between age, sex, H7N9 case status, case fatality, and the presence of neutralising autoantibodies were evaluated by logistic regression. Available whole-genome sequencing data from 26 individuals with neutralising autoantibodies were screened for variants in genes linked to IFN-I autoimmunity.
Findings: Neutralising autoantibodies against at least one IFN-I were detected in 19.1% (38/199) of patients but in only 1.1% (6/531) of controls, consistent with published general population data. Most patient sera targeted IFNα[SUB]2[/SUB] and/or IFNω (35/199), and 18.1% (36/199) neutralised even high IFN-I concentrations of 1-10 ng/ml. The presence of neutralising autoantibodies was associated with 8.2- to 25.3-fold higher odds of H7N9 infection (p < 0.0001), depending on antibody specificity and reference group. Autoantibody prevalence increased significantly with age in patients (44.8% ≥70 years; OR = 1.05; 95% CI 1.02-1.07; p = 0.0001), but was not associated with sex (OR for males vs. females = 0.52; 95% CI 0.23-1.14; p = 0.106). All selected sera containing neutralising autoantibodies blocked IFNα[SUB]2[/SUB]-induced antiviral activity in cell culture. No known genetic predisposition for IFN-I autoimmunity was identified.
Interpretation: Our findings suggest that IFN-I-targeting autoimmunity is associated with susceptibility to zoonotic IAV infection with the H7N9 subtype, and possibly also other subtypes, including panzootic H5N1. Given the ease of implementation, screening for anti-IFN-I autoantibodies could be readily integrated into surveillance or targeted testing. This could be relevant in environments with increased exposure to zoonotic IAVs.
Funding: Shenzhen Medical Research Fund, National Natural Science Foundation of China, Non-profit Central Research Institute Fund of Chinese Academy of Medical Sciences, Guangdong Provincial Science and Technology Program, Program for Youzuzhikeyan of Shenzhen University, German Research Foundation, Swiss National Science Foundation.
Keywords: Autoantibodies; H7N9; Influenza A virus; Type I interferon; Zoonosis.
. 2026 Jul 16:130:106387.
doi: 10.1016/j.ebiom.2026.106387. Online ahead of print.
Autoantibodies against type I interferons in patients with zoonotic H7N9 influenza: an observational case-control study
Yongkun Chen[SUP] 1 [/SUP], Jakob Ankerhold[SUP] 2 [/SUP], Tingting Jia[SUP] 3 [/SUP], Martin Wolkewitz[SUP] 4 [/SUP], Jonas Fuchs[SUP] 5 [/SUP], Lifang Yuan[SUP] 1 [/SUP], Tian Bai[SUP] 6 [/SUP], Kevin Groen[SUP] 7 [/SUP], Roger Kuratli[SUP] 7 [/SUP], Benjamin G Hale[SUP] 7 [/SUP], Georg Kochs[SUP] 5 [/SUP], Dayan Wang[SUP] 8 [/SUP], Martin Schwemmle[SUP] 5 [/SUP], Yuelong Shu[SUP] 9 [/SUP], Laura Graf[SUP] 10 [/SUP]
Affiliations
- PMID: 42462284
- DOI: 10.1016/j.ebiom.2026.106387
Background: The determinants of the species barrier preventing human infections with avian influenza A viruses (IAV) are incompletely understood. We previously identified loss-of-function variants of the interferon-regulated antiviral factor MxA as a genetic factor for increased susceptibility to infections with the H7N9 subtype. Given the central role of type I IFNs (IFN-I) in antiviral defence, we hypothesised that IFN-I-neutralising autoantibodies may similarly predispose to zoonotic H7N9 infection.
Methods: In this observational case-control study, serum samples collected between 2013 and 2017 from 199 Chinese patients with laboratory-confirmed H7N9 infection and 531 healthy, uninfected controls (269 poultry workers, 262 close contacts) were screened for IgG autoantibodies binding IFNα[SUB]2[/SUB], IFNβ[SUB]1b[/SUB], or IFNω using a multiplex bead-based assay. Positive samples were tested for IFN-neutralising activity in a luciferase-based reporter assay. To confirm their ability to block IFNα[SUB]2[/SUB]-mediated antiviral activity, selected samples (n = 19) were analysed in IAV infection experiments. Associations between age, sex, H7N9 case status, case fatality, and the presence of neutralising autoantibodies were evaluated by logistic regression. Available whole-genome sequencing data from 26 individuals with neutralising autoantibodies were screened for variants in genes linked to IFN-I autoimmunity.
Findings: Neutralising autoantibodies against at least one IFN-I were detected in 19.1% (38/199) of patients but in only 1.1% (6/531) of controls, consistent with published general population data. Most patient sera targeted IFNα[SUB]2[/SUB] and/or IFNω (35/199), and 18.1% (36/199) neutralised even high IFN-I concentrations of 1-10 ng/ml. The presence of neutralising autoantibodies was associated with 8.2- to 25.3-fold higher odds of H7N9 infection (p < 0.0001), depending on antibody specificity and reference group. Autoantibody prevalence increased significantly with age in patients (44.8% ≥70 years; OR = 1.05; 95% CI 1.02-1.07; p = 0.0001), but was not associated with sex (OR for males vs. females = 0.52; 95% CI 0.23-1.14; p = 0.106). All selected sera containing neutralising autoantibodies blocked IFNα[SUB]2[/SUB]-induced antiviral activity in cell culture. No known genetic predisposition for IFN-I autoimmunity was identified.
Interpretation: Our findings suggest that IFN-I-targeting autoimmunity is associated with susceptibility to zoonotic IAV infection with the H7N9 subtype, and possibly also other subtypes, including panzootic H5N1. Given the ease of implementation, screening for anti-IFN-I autoantibodies could be readily integrated into surveillance or targeted testing. This could be relevant in environments with increased exposure to zoonotic IAVs.
Funding: Shenzhen Medical Research Fund, National Natural Science Foundation of China, Non-profit Central Research Institute Fund of Chinese Academy of Medical Sciences, Guangdong Provincial Science and Technology Program, Program for Youzuzhikeyan of Shenzhen University, German Research Foundation, Swiss National Science Foundation.
Keywords: Autoantibodies; H7N9; Influenza A virus; Type I interferon; Zoonosis.